Biocon says 'all product approvals are legitimate' in bribery case for insulin approval
CBI says the accused was trying to exert undue influence on officers of CDSCO to waive the Phase III trial of "Insulin Aspart Injection".
biocon biologics
June 2022
February 2022
December 2021
November 2021
July 2021
January 2021
Bold bet! Biocon Biologics buys Viatris biosimilars assets for $3.33 billion
Viatris will receive $2 billion in cash and up to $335 million as additional payments expected to be paid in 2024.
Biocon wins US patent battle against Sanofi on insulin biosimilar
Semglee is the only interchangeable biosimilar to Lantus, used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes.
Walgreens to sell Biocon's insulin Semglee in the U.S.
Biocon Biologics targets to tap a $30 billion U.S. insulin market with two interchangeable insulins.
Covid-19 is an endemic, not pandemic: Mazumdar-Shaw
Kiran Mazumdar-Shaw, the Biocon chief, feels hospitalisation and not infection count matters in the fight against Coronavirus.
Mix and match vaccines, says Kiran Mazumdar-Shaw
In an exclusive conversation with Fortune India, the executive chairperson of Biocon says India should immediately start mixing and matching existing vaccines to accelerate the vaccination drive.
Syngene’s winning formula
Syngene International was started by Biocon in 1993 to provide research services for pharma companies. Three decades later, the entity wants to become a global science company in its own right.
Biocon’s biosimilar biz tops $4 bn in valuation
Abu Dhabi-based sovereign wealth fund ADQ has picked up 1.80% stake in Biocon Biologics for $75 million; The company already raised $255 million from global marquee investors last year.
